Study Suggests Genetics as a Cause, Not Just a ... - The New York …
Web2 days ago · May 6, 2024 Updated 12:19 p.m. ET. Scientists are proposing a new way of understanding the genetics of Alzheimer’s that would mean that up to a fifth of patients would be considered to have a ...
Silent brain changes precede Alzheimer’s. Researchers have new …
WebFeb 21, 2024 · Updated 2:26 PM PDT, February 21, 2024. WASHINGTON (AP) — Alzheimer’s quietly ravages the brain long before symptoms appear and now scientists have new clues about the dominolike sequence of those changes — a potential window to one day intervene.
Redefining Dementia Treatment: Berkeley Scientists Unveil Promising New ...
WebFeb 28, 2024 · In a study recently published in the journal Nature, the researchers reported that delivering a drug that forces the stress response to shut down saves cells that mimic a type of neurodegenerative disease known as early-onset dementia. The Role of the SIFI Complex in Neurodegeneration.
Lecanemab, the New Alzheimer’s Treatment: 3 Things To Know
WebUpdated: July 24, 2023.] The Food and Drug Administration (FDA) recently granted full approval to a new Alzheimer’s treatment called lecanemab, which has been shown to moderately slow cognitive and functional decline in early-stage cases of the disease.
New drug donanemab is 'a turning point in the fight against …
WebJul 17, 2023 · Full results about the Alzheimer's disease drug donanemab have been released today, supporting earlier trial results that suggested the breakthrough drug may slow down the progression of the disease. Dr Richard Oakley, Associate Director of Research and Innovation at Alzheimer’s Society, said:
Lecanemab in Early Alzheimer’s Disease | New England Journal of Medicine
WebNov 29, 2022 · Lecanemab reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with...
Start of new era for Alzheimer’s treatment — Harvard Gazette
WebJun 5, 2023 · Researchers say we appear to be at the start of a new era for Alzheimer’s treatment. Trial results published in January showed that for the first time a drug has been able to slow the cognitive decline characteristic of the disease. The drug, lecanemab, is a monoclonal antibody that works by binding to a key protein linked to the malady ...
NIH releases 2022 dementia research progress report
WebNovember 8, 2022. Alzheimer's Disease. NIH has released Advancing Alzheimer’s Disease and Related Dementias Research for All Populations: Prevent. Diagnose. Treat. Care. (PDF, 17M), a 2022 scientific progress report.
Large-scale study of brain proteins uncovers new clues to …
WebSep 29, 2022 · Through a large-scale analysis of tissue samples, NIA-funded researchers have discovered new disease-related changes in the brains of people who had died with Alzheimer’s disease. The study results, published in Nature Neuroscience, underscore the key role proteins may play in disease progression.
FDA fully approves Leqembi, first drug shown to slow Alzheimer's ...
WebJul 6, 2023 · In studies reviewed by the FDA, Leqembi appeared to slow declines in memory and thinking by about 27% after 18 months of treatment. It also dramatically reduced the sticky beta-amyloid plaques...
Skip to content